CytoDyn Activates 795M-Share Resale Registration — Massive Overhang Now Tradable
CYDY is trading near its 52-week low of $0.183 (9.3% above the low).
Summary
CytoDyn filed a prospectus supplement activating the resale of 794.97 million shares by selling stockholders — over half the current outstanding share count — with potential warrant exercise proceeds of up to $94.6 million.
Key Events · Financing and Capital Events · CYDY
-
795M-Share Resale Registration Activated
The 424B3 prospectus supplement makes 410,046,456 shares of common stock and 384,925,833 shares underlying warrants immediately tradable by selling stockholders — 794,972,289 shares total.
-
Overhang Exceeds Half of Outstanding Shares
The 794.97 million registered shares represent approximately 54% of the 1,469,518,019 shares outstanding as of September 24, 2026, creating a substantial potential supply overhang.
-
Company Receives No Proceeds from Resales
CytoDyn will not receive any proceeds from sales by selling stockholders; all proceeds go to the selling stockholders themselves.
-
Warrant Exercise Could Bring $94.6M
If all 384.9 million warrants are exercised for cash at prices ranging from $0.09387 to $0.50 per share, the company could receive up to approximately $94.6 million for working capital.
Analysis · CYDY · Life Sciences
A prospectus supplement from CytoDyn makes 794.97 million shares immediately available for sale by selling stockholders — roughly 54% of the 1.47 billion shares outstanding. The company receives no proceeds from these sales, but could receive up to $94.6 million if all 384.9 million warrants are exercised for cash. This comes against a backdrop of a going-concern warning and a $42.7 million net loss disclosed in the August 10-K. The registration does not force sales, but it removes the last barrier for hundreds of selling stockholders to exit, creating a persistent overhang on a stock already trading at $0.20.
How filings like this one have moved
In the 30 days to Oct 22, 2026, 29.4% of the 1560 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CYDY was trading at $0.20 on OTC in the Life Sciences sector, with a market capitalization of approximately $293.8M. The 52-week trading range was $0.18 to $0.40. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.